Kivizidiale (Timolol, Travoprost)

Timolol reduces the production of aqueous humor by blocking beta‑adrenergic receptors in the ciliary body, while Travoprost increases uveoscleral outflow by acting as a prostaglandin F2α analog. Together they address both the inflow and outflow pathways, providing a synergistic pressure‑lowering effect.

The dosing regimen for Kivizidiale is determined by the prescribing ophthalmologist based on the individual patient's intraocular pressure, response to therapy, and tolerance. Typically, one drop is instilled in the affected eye(s) once daily, but the exact schedule should follow the prescriber’s instructions.

Safety data for Kivizidiale in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers should discuss individual risks and consider alternative treatments when appropriate.

To request Kivizidiale, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapies, Kivizidiale combines a beta‑blocker and a prostaglandin analog, offering dual mechanisms that can achieve greater intraocular pressure reduction with a single daily dose. This may improve adherence versus using two separate drops, though individual response varies.

Kivizidiale should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light and moisture, and discard any solution that appears discolored or contains particles.

The medication is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to form a pocket, and instill one drop into the conjunctival sac. Close the eye gently and avoid blinking excessively for a few seconds.

Serious risks include severe allergic reactions in the eye, sudden loss of vision, marked increase in intraocular pressure despite treatment, and systemic beta‑blocker effects such as bradycardia, hypotension, or bronchospasm, especially in patients with pre‑existing cardiac or respiratory conditions.

Kivizidiale is contraindicated in patients with known hypersensitivity to timolol, travoprost, or any excipients in the formulation. It should also be avoided in individuals with severe asthma, chronic obstructive pulmonary disease, or certain cardiac conduction disorders where systemic beta‑blockade could be harmful.